TRUL has added 35% in a month and 24% in a single week, yet the stock's most interesting tension now sits in its rapidly expanding valuation multiples and a looming August earnings date that will test whether the rally has fundamental support.
The valuation re-rating has been sharp. Price-to-earnings has expanded by roughly 83% over the past 30 days, reaching 68x. EV/EBITDA has climbed to 7.0x, up about 14% on the same measure over the month. Price-to-book has risen to 1.97x, gaining about 0.75 points in 30 days. These are meaningful multiple expansions for a cannabis operator — the stock is being priced for a recovery story, not a discount. The short score of 31.4 ranks in the 84th percentile for short score rank, meaning short sellers are less crowded in this name relative to the broader universe, which has allowed the price to run with little resistance from the bear side.
The lending market remains extraordinarily relaxed — and that has not changed since the prior note. Availability runs at roughly 1,542%, meaning there are more than 15 shares available to borrow for every one currently shorted. That figure has actually widened sharply from a week ago, when it was closer to 4,270% at the June 9 peak before pulling back, and the direction is described as falling — availability tightened from above 4,000% in early June to current levels. Still, 1,542% is far above the 52-week low of 164%, which means borrow conditions remain extremely loose by any historical standard. Short interest itself is negligible at just 0.27% of free float. Cost to borrow has drifted lower on the week, easing to 3.85% from around 4.6% a week prior, though it remains about 47% above its level from a month ago — a minor increase in borrow cost that reflects some marginal uptick in activity without any meaningful squeeze dynamic.
The earnings picture adds an important layer to the valuation story. The next event is scheduled for August 5, and recent history on reactions has been consistently negative. The May 8 print produced a one-day fall of 8.2% and a five-day move of negative 20.6%. The May 7 event registered a one-day drop of 12.4% and a five-day decline of nearly 20%. Those are punishing post-earnings moves for a stock now priced at 68x earnings. The EPS surprise factor score of just 6 out of 100 confirms Trulieve has a weak track record of beating estimates — making the current multiple expansion a high-conviction bet on operational improvement rather than a reflection of consistent delivery.
The institutional picture is relatively thin. Marex Group holds about 5.1% of shares, Nomura around 4.2%, though the Nomura position was last reported in September 2024. Insider data is stale — the last material transaction on record was founder Kimberly Rivers' March sale of 2.5 million shares at roughly CAD 6.35, a price the stock has since more than doubled past. No insider buying has been recorded in the trailing window. The most recent March reporting shows Thad Beshears added a modest 19,003 shares and Richard May added 79,400 shares, but at values too small to signal strong conviction at the executive level.
With August 5 now the clear focal point, the question is whether the valuation expansion that has driven the 30-day rally can be sustained into an earnings print where the stock's own history argues for sharp moves — and rarely in the right direction.
See the live data behind this article on ORTEX.
Open TRUL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
